Previous Close | 11.94 |
Open | 11.87 |
Bid | 12.00 x 3100 |
Ask | 12.06 x 3000 |
Day's Range | 11.72 - 11.94 |
52 Week Range | 8.74 - 13.62 |
Volume | |
Avg. Volume | 10,355,431 |
Market Cap | 13.966B |
Beta (5Y Monthly) | 1.14 |
PE Ratio (TTM) | 235.20 |
EPS (TTM) | 0.05 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | 0.48 (4.08%) |
Ex-Dividend Date | Mar 08, 2024 |
1y Target Est | 14.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for VTRS
Investors can collect a high yield with Viatris, but is it a risky payout to rely on?
These companies aren't popular on the market right now, but income investors will like them.
The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the companies said on Monday. The companies were reviewing the content of the health regulator's so called complete response letter (CRL) and would soon determine the appropriate next steps, they said, without disclosing further details. Mapi Pharma did not immediately respond to Reuters requests for additional details on the contents of the CRL, which indicates that an application would not be approved in its present form and requires more information.